Synapse

← Portal hypertension & cirrhosis

Papers in Portal hypertension & cirrhosis

Page 2 · newest first

  1. Pharmacotherapy for Cirrhosis in JapanPortal hypertension & cirrhosis · 2025
  2. The Prognostic Significance of Handgrip Strength in Cirrhosis: Simplicity Is the Ultimate SophisticationPortal hypertension & cirrhosis · 2025
  3. Portal Hypertension—Noninvasive Multiparametric Ultrasound‐Based Criteria and MeasurementsPortal hypertension & cirrhosis · 2025
  4. A Combined Model of Spleen Stiffness and Baveno VII Criteria for Clinically Significant Portal Hypertension in Compensated Advanced Chronic Liver Disease: An International Multicenter StudyPortal hypertension & cirrhosis · 2025
  5. LiverRCT IIT : Promoting Investigator‐Initiated Randomized Controlled Trials for the Key Clinical Issues in Liver Disease Prevention and TreatmentPortal hypertension & cirrhosis · 2025
  6. Radiomic Analysis of Contrast‐Enhanced CT Predicts Recompensation in Hepatitis B‐Related Decompensated CirrhosisPortal hypertension & cirrhosis · 2025
  7. The Chinese Herbal TiaoGanXiaoZhi Formula Alleviates the Progression of Metabolic‐Associated Fatty Liver Disease by Regulating the Gut MicrobiotaPortal hypertension & cirrhosis · 2025
  8. Research Progress of Noninvasive Evaluation of Portal Hypertension by Blood‐Based TestsPortal hypertension & cirrhosis · 2025
  9. Resmetirom and Thyroid Hormone Receptor‐Targeted Treatment for Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD)Portal hypertension & cirrhosis · 2025
  10. Application of graph theory in liver research: A reviewPortal hypertension & cirrhosis · 2024
  11. Dawn of an era of effective treatments for MAFLDPortal hypertension & cirrhosis · 2024
  12. Molecular mechanisms of hepatic lipid metabolism disorders: Focus on mitochondrial quality controlPortal hypertension & cirrhosis · 2024
  13. Portal hypertension as an independent risk factor for cirrhotic cardiomyopathy: An investigation on its mechanism based on bioinformatics analysisPortal hypertension & cirrhosis · 2024
  14. Psoas muscle index in sarcopenia following transjugular intrahepatic portosystemic shunt: A multicenter, retrospective studyPortal hypertension & cirrhosis · 2024
  15. Exploring the predictive value of serum lipids for short‐term prognosis in patients with acute‐on‐chronic liver failurePortal hypertension & cirrhosis · 2024
  16. Nationwide survey analysis of esophagogastric varices in portal hypertension based on endoscopic management in ChinaPortal hypertension & cirrhosis · 2024
  17. Appraising the causal effects of circulating micronutrients on liver cirrhosis: Evidence from large‐scale Mendelian randomization analysisPortal hypertension & cirrhosis · 2024
  18. Bibliometric and visualized analysis of the correlation between sarcopenia and chronic liver diseases from 2000 to 2023Portal hypertension & cirrhosis · 2024
  19. Role of post‐hepatectomy portal hypertension in predicting the outcome of hepatocellular carcinoma after curative resectionPortal hypertension & cirrhosis · 2024
  20. Application of subharmonic‐aided pressure estimation in a patient with giant hepatic cyst: A case reportPortal hypertension & cirrhosis · 2024
  21. Tumor budding is a meaningful prognostic marker in patients with hepatocellular carcinoma after curative hepatectomyPortal hypertension & cirrhosis · 2024
  22. Endoscopic ultrasound‐guided portal pressure gradient identifies patients with previously undiagnosed clinically significant portal hypertensionPortal hypertension & cirrhosis · 2024
  23. Sequential or simultaneous transarterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma within the Milan criteria: A retrospective real‐world studyPortal hypertension & cirrhosis · 2024
  24. Progress in the diagnosis and treatment of graft fibrosis after liver transplantationPortal hypertension & cirrhosis · 2024
  25. Global status and trends in hepatitis B virus DNA mutation research from 2003 to 2022: A comprehensive bibliometric viewPortal hypertension & cirrhosis · 2024
  26. Dual neovascular targets of vascular endothelial growth factor receptors and platelet‐derived growth factor receptor ameliorate thioacetamide induced liver fibrosis in ratsPortal hypertension & cirrhosis · 2024
  27. Serum markers for detecting histological features of autoimmune hepatitis and predicting prognosis in patients with antinuclear antibody‐positive drug‐induced liver injuryPortal hypertension & cirrhosis · 2024
  28. One‐year status of hepatic venous pressure gradient measurement from 85 hospitals in ChinaPortal hypertension & cirrhosis · 2024
  29. Innovations in endoscopic ultrasound for portal hypertension and its role in managing complications in clinical practice: Lessons learned from a tertiary referral public hospitalPortal hypertension & cirrhosis · 2024
  30. Treatment strategy for erythropoietic protoporphyria accompanied by severe abdominal pain and liver injuryPortal hypertension & cirrhosis · 2024
  31. Global burden trends of MAFLD‐related liver cancer from 1990 to 2019Portal hypertension & cirrhosis · 2023
  32. Comparison of patients with hepatitis B virus‐associated hepatocellular carcinoma: Data from two hospitals from Turkey and ChinaPortal hypertension & cirrhosis · 2023
  33. Sleep disturbances in patients with cirrhosis: Pursuing just rightPortal hypertension & cirrhosis · 2023
  34. Prevalence and risk factors for minimal hepatic encephalopathy in cirrhotic patients with different etiologiesPortal hypertension & cirrhosis · 2023
  35. Ten important original articles in the field of cirrhosis and portal hypertension from ChinaPortal hypertension & cirrhosis · 2023
  36. Comparison of prevention and treatment of portal vein thrombosis between proximal splenic vein ligation followed by postoperative transcatheter anticoagulant therapy and systemic anticoagulant therapy in patients with cirrhotic portal hypertensionPortal hypertension & cirrhosis · 2023
  37. Plasma copeptin concentration is a predictor of tolvaptan efficacy in patients with hepatic ascitesPortal hypertension & cirrhosis · 2023
  38. MicroRNAs as critical regulators in liver fibrosisPortal hypertension & cirrhosis · 2023
  39. Immunogenicity and safety of a booster COVID‐19 vaccination in patients with chronic liver disease: A multicenter studyPortal hypertension & cirrhosis · 2023
  40. Investigation on the short‐term outcome and prognostic impact of predisposition, and precipitants in inpatients with chronic liver disease from Chinese AcuTe on CHronic LIver FailurE (CATCH‐LIFE) cohortsPortal hypertension & cirrhosis · 2023
  41. Portal vein thrombosis in liver cirrhosis: An updated overviewPortal hypertension & cirrhosis · 2023
  42. Quantitative computed tomography‐based approaches for noninvasive diagnosis of portal hypertension in patients with cirrhosisPortal hypertension & cirrhosis · 2023
  43. Hepatic venous pressure gradient measurement guiding nonselective beta‐blocker therapy in a patient with clinically significant portal hypertensionPortal hypertension & cirrhosis · 2023
  44. Stories behind the coverPortal hypertension & cirrhosis · 2023
  45. Subharmonic aided pressure estimation in portal hypertension: A noninvasive ultrasound‐based technique to assess portal pressure gradientPortal hypertension & cirrhosis · 2023
  46. A patient with dyskeratosis congenita and portal hypertensionPortal hypertension & cirrhosis · 2023
  47. Three‐dimensional magnetic resonance elastography in chronic liver diseasePortal hypertension & cirrhosis · 2023
  48. Global scientific trends on portal hypertension and cirrhosis in the 21st century: A bibliometric and visualized analysisPortal hypertension & cirrhosis · 2023
  49. Traditional Chinese medicine targets on hepatic stellate cells for the treatment of hepatic fibrosis: A mechanistic reviewPortal hypertension & cirrhosis · 2023
  50. Status of transjugular intrahepatic portosystemic shunt for portal hypertension in China: A national survey analysisPortal hypertension & cirrhosis · 2023